Ziv-aflibercept in macular disease.

Background/aims: Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept. Our purpose is to determine if ziv-aflibercept can be used in AMD and DME without ocular toxicity, to test the stability of ziv-aflibercept, and to do a cost analysis.

Ocular coherence tomography of symptomatic phototoxic retinopathy after cataract surgery: a case report.

Introduction: High-resolution ocular coherence computed tomography enables unprecedented visualization of the retinal microarchitecture. To the best of our knowledge, this is the first report of high-resolution ocular coherence tomography findings in the healed form of photic post-cataract retinopathy.

Case Presentation: A 76-year-old Caucasian man complained of paracentral scotoma, persisting for six weeks after cataract surgery.